Chemical Biology & Drug Design

Scope & Guideline

Transforming research into real-world health solutions.

Introduction

Immerse yourself in the scholarly insights of Chemical Biology & Drug Design with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN1747-0277
PublisherWILEY
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 2006 to 2024
AbbreviationCHEM BIOL DRUG DES / Chem. Biol. Drug Des.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

The journal "Chemical Biology & Drug Design" focuses on the integration of chemical biology and medicinal chemistry to develop new therapeutic agents and understand their mechanisms of action. It aims to bridge the gap between chemistry and biology, emphasizing innovative drug design, synthesis, and evaluation methodologies.
  1. Medicinal Chemistry:
    The journal emphasizes the design and synthesis of novel chemical compounds with potential therapeutic applications, particularly in cancer, infectious diseases, and chronic conditions.
  2. Chemical Biology:
    Research that explores the interactions between biological systems and chemical entities, including the mechanisms behind drug action and biological pathways.
  3. Drug Development and Design:
    The journal features works related to the development of new drugs, including formulation strategies, delivery systems, and efficacy evaluations.
  4. Network Pharmacology:
    A focus on understanding the multi-target interactions of drugs within biological networks, which is essential for elucidating complex disease mechanisms.
  5. In Silico Studies:
    Emphasizes computational approaches in drug discovery, including molecular docking, QSAR modeling, and machine learning applications to predict biological activity.
  6. Natural Products Chemistry:
    Explores the therapeutic potential of natural compounds and their derivatives, focusing on their isolation, structural elucidation, and biological activities.
Recent publications in "Chemical Biology & Drug Design" indicate a shift towards innovative and interdisciplinary approaches in drug discovery and development. The following themes have emerged as significant focuses of research.
  1. Targeted Cancer Therapies:
    An increasing number of studies are focusing on targeted therapies that leverage specific molecular pathways in cancer treatment, reflecting the growing understanding of tumor biology.
  2. Combination Therapies:
    Research is trending towards exploring the efficacy of combination therapies that utilize multiple agents to enhance therapeutic outcomes and overcome resistance mechanisms.
  3. Biologics and Biopharmaceuticals:
    The emergence of biologics as therapeutic agents, including monoclonal antibodies and protein-based drugs, is gaining traction, emphasizing the need for advanced drug design techniques.
  4. Machine Learning and AI in Drug Discovery:
    The integration of machine learning and artificial intelligence into drug discovery processes is becoming increasingly prominent, aiding in predictive modeling and optimization of drug candidates.
  5. Natural Product Derivatives:
    There is a growing interest in the modification of natural products to enhance their pharmacological properties, with a focus on their potential as leads for new drug development.
  6. Nanotechnology in Drug Delivery:
    Research is increasingly focusing on the application of nanotechnology for drug delivery systems, enhancing the bioavailability and targeting of therapeutic agents.

Declining or Waning

While the journal maintains a robust focus on various emerging themes, certain areas have seen a decline in prominence over recent years. This may reflect shifts in research priorities or advancements in specific methodologies.
  1. Traditional Antimicrobial Agents:
    Research focusing on conventional antibiotics and their mechanisms has become less prevalent as the field moves towards exploring novel and multi-targeted therapeutic strategies.
  2. Single-Target Drug Design:
    There is a noticeable decrease in studies centered around single-target drugs, as the complexity of diseases has led to a shift towards multi-target approaches and combination therapies.
  3. In vitro Only Studies:
    Research that solely relies on in vitro models without in vivo validation has waned, as the scientific community increasingly emphasizes the importance of comprehensive in vivo studies to support findings.
  4. Synthetic Methods with Limited Applicability:
    The use of traditional synthetic methods without innovative adaptations or applications in drug design has seen a decline, as researchers seek more versatile and efficient synthetic strategies.

Similar Journals

Current Computer-Aided Drug Design

Transforming Pharmacology with Cutting-Edge Design Techniques
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1573-4099Frequency: 4 issues/year

Current Computer-Aided Drug Design, published by BENTHAM SCIENCE PUBL LTD, is a pivotal journal dedicated to the integration of computer-aided methodologies within the drug design process. With its ISSN 1573-4099 and E-ISSN 1875-6697, this journal serves as a vital resource for researchers, professionals, and students interested in advancing the fields of pharmacology and molecular medicine. Operating under a framework that spans from 2006 to 2024, it aims to foster innovative approaches and discussions surrounding drug design strategies, computational techniques, and the therapeutic potential of novel compounds. Although it currently holds a Q4 rating in Drug Discovery and Molecular Medicine as well as a Q3 in Medicine (miscellaneous) within the 2023 category quartiles, the journal continues to enhance its visibility and relevance in the academic community. Its Scopus rankings reflect its commitment to quality research, positioning it in the context of drug discovery and molecular studies. As the field of drug design evolves, Current Computer-Aided Drug Design remains an essential platform for disseminating cutting-edge findings and facilitating collaboration among specialists aiming for significant advancements in drug development.

ChemMedChem

Exploring the nexus of chemistry and pharmacology.
Publisher: WILEY-V C H VERLAG GMBHISSN: 1860-7179Frequency: 24 issues/year

ChemMedChem is a leading international journal published by WILEY-V C H VERLAG GMBH in the United Kingdom, specializing in the interdisciplinary fields of medicinal chemistry and drug discovery. With a commendable impact factor that places it in the Q1 quartile for Organic Chemistry and among the Q2 ranks in several other key categories including Biochemistry, Molecular Medicine, and Pharmacology, ChemMedChem serves as a vital platform for the dissemination of innovative research and transformative insights in the development of pharmaceutical agents. Since its inception in 2006, this journal has been at the forefront of advancing knowledge that bridges the gap between fundamental research and practical applications in medicine, making it an essential resource for researchers, professionals, and students alike. Although it currently does not offer Open Access options, the journal ensures high-quality peer-reviewed content that engages its audience and fosters collaborative scientific discourse.

Anti-Cancer Agents in Medicinal Chemistry

Pioneering research in medicinal chemistry for cancer treatment.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1871-5206Frequency: 10 issues/year

Anti-Cancer Agents in Medicinal Chemistry is a pivotal journal in the realm of cancer research, published by Bentham Science Publishers in the United Arab Emirates. With an ISSN of 1871-5206 and an E-ISSN of 1875-5992, this esteemed journal has been disseminating high-quality research since its inception in 2006, and is set to continue through 2024. The journal is categorized in the third quartile (Q3) across key areas including Cancer Research, Molecular Medicine, and Pharmacology, highlighting its essential role in providing valuable insights to the scientific community. Despite its open-access status being unspecified, researchers benefit from the rigorous peer-review process ensuring the publication of significant advancements. The journal ranks well within Scopus, particularly in the fields of Pharmacology and Cancer Research, which positions it as a notable resource for professionals, students, and researchers aiming to deepen their knowledge in anti-cancer strategies. Through its comprehensive scope, the journal aims to bridge the gap between medicinal chemistry and clinical applications, making it an indispensable tool for those dedicated to advancing cancer therapeutics.

RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY

Advancing Knowledge in Bioorganic Chemistry
Publisher: MAIK NAUKA/INTERPERIODICA/SPRINGERISSN: 1068-1620Frequency: 7 issues/year

Russian Journal of Bioorganic Chemistry (ISSN: 1068-1620, E-ISSN: 1608-330X), published by MAIK Nauka/Interperiodica/Springer, serves as a vital resource for researchers and professionals in the fields of bioorganic chemistry, biochemistry, and organic chemistry. With a focus on the integration of organic chemistry principles with biological processes, this journal aims to disseminate significant findings and advancements from both theoretical and practical perspectives. Although currently not open access, the journal retains a dedication to high-quality, peer-reviewed content, contributing to its reputation within the academic community. The 2023 Scopus rankings position it within the Q4 category for both biochemistry and organic chemistry, indicating its critical niche within these disciplines amid a competitive landscape. Since its inception in 1996, the journal has continued to evolve, providing enriching insights and fostering collaborations among scholars and practitioners alike, with publication converging up to the year 2024. By exploring complex biomolecular interactions and the synthesis of biologically relevant compounds, the Russian Journal of Bioorganic Chemistry remains a significant platform for advancing knowledge and innovation in the life sciences.

Future Medicinal Chemistry

Advancing the frontiers of drug discovery.
Publisher: Newlands Press LtdISSN: 1756-8919Frequency: 24 issues/year

Future Medicinal Chemistry is a premier journal dedicated to the rapidly evolving fields of drug discovery, pharmacology, and molecular medicine. Published by Newlands Press Ltd in the United Kingdom, this journal has garnered significant attention within the academic community, evidenced by its 2023 category rankings in Scopus, placing it in the Q2 quartile for Drug Discovery and the Q3 quartiles for both Molecular Medicine and Pharmacology. With an ISSN of 1756-8919 and an E-ISSN of 1756-8927, Future Medicinal Chemistry has been a cornerstone of scholarly discourse since its inception in 2009, continuously contributing to the advancement of knowledge and discussion in medicinal chemistry. The journal is committed to publishing high-quality, peer-reviewed research that addresses the challenges and innovations in drug development and therapeutic strategies, making it an essential resource for researchers, professionals, and students seeking to stay at the forefront of these critical fields. Engage with the latest findings and methodologies that shape the future of medicine by exploring the wealth of information offered within Future Medicinal Chemistry.

Journal of Natural Medicines

Pioneering Discoveries in Organic Chemistry and Herbal Science
Publisher: SPRINGER JAPAN KKISSN: 1340-3443Frequency: 4 issues/year

Journal of Natural Medicines, published by SPRINGER JAPAN KK, is a leading academic journal that plays a pivotal role in the advancement of research in the fields of Complementary and Alternative Medicine, Drug Discovery, Molecular Medicine, Organic Chemistry, and Pharmaceutical Science. Established in 1994 and set to continue until 2024, this journal serves as a vital conduit for the dissemination of groundbreaking research and innovative ideas that bridge traditional medicinal knowledge and modern scientific inquiry. With its impressive ranking in Scopus—ranking #12 out of 105 in Complementary and Alternative Medicine and holding a Q1 category quartile for 2023—it stands as a reputable source for high-quality, peer-reviewed articles. The journal's commitment to excellence is further underscored by its inclusion in the Springer network, providing researchers, professionals, and students with valuable insights and the latest developments in natural medicines. Although this journal operates under a subscription model, its profound impact on these interdisciplinary fields makes it an essential resource for anyone engaged in the study or practice of natural medicinal therapies.

CHEMICAL & PHARMACEUTICAL BULLETIN

Pioneering research for a healthier tomorrow.
Publisher: PHARMACEUTICAL SOC JAPANISSN: 0009-2363Frequency: 12 issues/year

CHEMICAL & PHARMACEUTICAL BULLETIN, published by the Pharmaceutical Society of Japan, has been a cornerstone in the fields of chemistry, drug discovery, and medicine since its inception in 1958. With an ISSN of 0009-2363, this esteemed journal offers a platform for the dissemination of innovative research and critical insights contributing to these dynamic disciplines. Housed in Tokyo, Japan, it is strategically poised to bridge the gap between chemical sciences and pharmaceutical applications. Although the journal operates under a traditional subscription model and does not currently offer open access, it maintains a solid reputation, evidenced by its Q3 category rankings in multiple relevant fields and its percentile positions in Scopus, specifically 48th in General Chemistry and 30th in Drug Discovery. Researchers, professionals, and students alike will find invaluable resources within its pages, as it diligently covers shifting paradigms and emerging methodologies critical to advancing both theoretical understanding and practical applications in the pharmaceutical realm.

CHEMICO-BIOLOGICAL INTERACTIONS

Illuminating Chemical and Biological Synergies
Publisher: ELSEVIER IRELAND LTDISSN: 0009-2797Frequency: 18 issues/year

CHEMICO-BIOLOGICAL INTERACTIONS is a premier journal published by Elsevier Ireland Ltd, dedicated to advancing the field of chemical and biological interactions since its inception in 1969. With a robust focus on pharmacology and toxicology, the journal holds a prestigious Q1 ranking in both Medicine (miscellaneous) and Toxicology, reflecting its significance in disseminating influential research. As part of the Scopus database, it ranks #21 out of 133 journals in Toxicology, positioning it in the 84th percentile and ensuring high visibility for cutting-edge studies. This scholarly platform serves as a crucial resource for researchers, professionals, and students who seek reliable and innovative findings at the intersection of chemistry and biology. While currently not open access, CHEMICO-BIOLOGICAL INTERACTIONS provides a comprehensive collection of articles that contribute to the ongoing dialogue in toxin research and its implications on medicinal chemistry, thereby fostering advancements in public health and safety.

Records of Natural Products

Harnessing Nature's Bounty for Scientific Progress
Publisher: ACG PUBLICATIONSISSN: 1307-6167Frequency: 6 issues/year

Records of Natural Products is a distinguished journal focused on the dynamic fields of Drug Discovery, Organic Chemistry, Pharmacology, and Plant Science. Published by ACG PUBLICATIONS in Turkey, this journal serves as a vital platform for disseminating innovative research findings and advancements in natural product studies. With its convergence spanning from 2009 to 2024, Records of Natural Products holds a commendable position in the academic realm, featuring a 2023 Q3 ranking in Drug Discovery and Organic Chemistry, alongside a notable Q2 ranking in Plant Science. Despite its current lack of open access, the journal is committed to providing quality content that enriches the understanding of natural products and their potential applications. Researchers and professionals alike can benefit from the journal's insights, which not only contribute to scientific knowledge but also facilitate advancements in pharmaceuticals and sustainable practices. By exploring the rich tapestry of natural product research, this journal underscores its importance as a leading resource for professionals dedicated to enhancing the efficacy and application of natural compounds.

European Journal of Medicinal Chemistry Reports

Shaping therapeutic innovations with high-quality research.
Publisher: ELSEVIERISSN: 2772-4174Frequency: 3 issues/year

European Journal of Medicinal Chemistry Reports, published by ELSEVIER, is a vital platform dedicated to advancing the field of medicinal chemistry through open access communication of high-quality research. With an impact factor reflecting its growing influence, this journal has rapidly established a reputation for scholarly excellence since its launch in 2021. It serves as a converging point for innovative studies and reviews that span the disciplines of chemistry and molecular medicine, reflected in its Q2 and Q3 quartile rankings in relevant categories for 2023. Situated in France, the journal is accessible globally, ensuring that researchers, professionals, and students can easily engage with significant findings and methodologies in medicinal chemistry. The open access model facilitates the dissemination of knowledge, bridging gaps between laboratory research and practical applications in drug development. By fostering collaboration and highlighting emerging trends, the European Journal of Medicinal Chemistry Reports plays a crucial role in shaping the future of therapeutic innovations.